Rituximab in the treatment of high responding inhibitors in severe haemophilia A

The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with i...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2006-01, Vol.12 (1), p.95-99
Main Authors: MOSCHOVI, M., ARONIS, S., TRIMIS, G., PLATOKOUKI, H., SALAVOURA, K., TZORTZATOU‐STATHOPOULOU, F.
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antibody Formation - immunology
Antigens, CD19 - immunology
Child, Preschool
children
Factor VIII - antagonists & inhibitors
Factor VIII - immunology
Hemophilia A - immunology
Hemophilia A - therapy
high responding inhibitors
Humans
Immune Tolerance - immunology
immune tolerance therapy
Immunity, Cellular - immunology
Immunoglobulin G - blood
Immunoglobulin M - blood
Immunologic Factors - adverse effects
Immunologic Factors - immunology
Immunologic Factors - therapeutic use
Immunotherapy - methods
Male
Quality of Life
Rituximab
rituximab (anti‐CD20)
severe haemophilia
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60–80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to
ISSN:1351-8216
1365-2516
DOI:10.1111/j.1365-2516.2006.01185.x